

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

OVERSEAS REGULATORY ANNOUNCEMENT

**LEGEND BIOTECH USA INC. ENTERS INTO MASTER MANUFACTURING AND
SUPPLY SERVICES AGREEMENT WITH NOVARTIS PHARMACEUTICALS
CORPORATION**

This announcement is made by the board of directors (the “**Board**”) of GenScript Biotech Corporation (the “**Company**”) pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Legend Biotech Corporation (“**Legend Biotech**”), a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, has filed a Form 6-K with the United States Securities and announced that on 27 March 2024, Legend Biotech USA Inc. (“**Legend USA**”), a wholly-owned subsidiary of Legend Biotech, Janssen Pharmaceuticals Inc. (“**Janssen**” and together with Legend USA, the “**Collaboration Partners**”) and Novartis Pharmaceuticals Corporation (“**Novartis**”) entered into a Master Manufacturing and Supply Services Agreement for BCMA CAR-T Product, pursuant to which Novartis will perform contract manufacturing services for the Collaboration Partners for the clinical and commercial supply of ciltacabtagene autoleucel (cilta-cel) to supplement the Collaboration Partners’ manufacturing capabilities. For details, please refer to the attachment, which is the full Form 6-K as published on the SEC’s website available at <https://www.sec.gov/Archives/edgar/data/1801198/000180119824000026/0001801198-24-000026-index.html>.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
GenScript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 1 April 2024

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

** For identification purposes only*

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

Date of Report: March 29, 2024

Commission File Number: 001-39307

Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)

**2101 Cottontail Lane
Somerset, New Jersey 08873**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Legend Biotech USA Inc. Enters into Master Manufacturing and Supply Services Agreement with Novartis Pharmaceuticals Corporation

On March 27, 2024, Legend Biotech USA Inc. (“**Legend**”), a wholly-owned subsidiary of Legend Biotech Corporation (the “**Company**”), Janssen Pharmaceuticals Inc. (“**Janssen**” and together with Legend, the “**Collaboration Partners**”) and Novartis Pharmaceuticals Corporation (“**Novartis**”) entered into a Master Manufacturing and Supply Services Agreement for BCMA CAR-T Product (the “**Agreement**”), pursuant to which Novartis will perform contract manufacturing services for the Collaboration Partners for the clinical and commercial supply of ciltacabtagene autoleucel (cilta-cel) (the “**Product**”) to supplement the Collaboration Partners’ manufacturing capabilities.

The Agreement is effective as of March 27, 2024 with an initial term through December 31, 2029, unless terminated earlier. The Agreement may be terminated (i) by the Collaboration Partners at any time for convenience after notice is provided for a specified period, (ii) if a party commits an uncured material breach of the Agreement, (iii) by the Collaboration Partners if Novartis undergoes a change in control, (iv) upon the occurrence of specified events of insolvency of Janssen or Novartis or (v) by the Collaboration Partners, in the event Novartis has not provided certain regulatory documentation for a Qualified Suite (as defined below) within by a specified deadline or in the event of certain performance failures by Novartis. Additionally, Qualified Suites (defined below) may be terminated (the “**Released Suites**”) after a specified notice period in the event of certain instances of performance failures by Novartis or in the event Novartis has not provided certain regulatory documentation for a Qualified Suite (as defined below) within by a specified deadline.

The Agreement requires Novartis to initiate activities to manufacture the Product in a specified number of qualified suites, which are suites that have been reserved by the Collaboration Partners to perform the contract manufacturing services for the Product after receipt of regulatory approval (the “**Qualified Suites**”). The Collaboration Partners will work with Novartis to facilitate the exchange of information necessary for Novartis to perform the contract manufacturing services and to obtain the applicable licenses and permits.

The Agreement requires the Collaboration Partners to purchase a specified percentage of the capacity of Qualified Suites for each 6-month period under the Agreement (the “**Volume Commitment**”), subject to adjustment for any Released Suites. If the Collaboration Partners fail to purchase sufficient batches to achieve the Volume Commitment (other than for exceptions specified in the Agreement), the Collaboration Partners are required to pay Novartis the amount to make up the deficit, subject to the Collaboration Partners’ ability to carry-over a certain percentage of any overachievement of the Volume Commitment during a six-month period to an immediately subsequent or prior six-month period during the same calendar year to cure any deficit. The Agreement also includes specified performance metrics (“**KPIs**”) that Novartis will be expected to meet when performing the contracting manufacturing services. The Agreement includes certain remedies if Novartis does not meet its KPIs.

The Agreement includes specified tiered pricing based upon, among other factors, the number of batches ordered by the Collaboration Partners during the applicable calendar year. In addition, the Collaboration Partners will be required to reimburse Novartis for costs of certain raw materials used in manufacturing the Product.

The Agreement also includes customary representations and warranties and covenants relating to, among other things, forecasts, ordering, delivery and payments, handling and transport, intellectual property, responsibility for non-conforming product, confidentiality and indemnification.

The foregoing description of the terms of the Agreement is not complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which the Company will file as an exhibit to the Company’s annual report on Form 20-F for the fiscal year ending December 31, 2024.

This Form 6-K shall be deemed to be incorporated by reference in the registration statements of the Company on Form F-3 (Nos. 333-278050, 333-257625, and 333-272222) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LEGEND BIOTECH CORPORATION

Date: March 29, 2024

By: /s/ Ying Huang

Name: Ying Huang, Ph.D.

Title: Chief Executive Officer
